Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review explores how molecular profiling in atopic dermatitis has led to new therapeutic developments, detailing approved and potential treatments, and discusses similar advances in alopecia areata; it reports no new results.

In this retrospective cohort study, researchers found that Taiwanese mothers with atopic dermatitis had a higher risk of various pregnancy complications and that their children were more likely to develop certain conditions like AD, asthma, and ADHD, compared to non-AD mothers and their children.

In this study, topical naringin was found to significantly improve dermatitis severity and reduce inflammatory markers in a mouse model of atopic dermatitis, suggesting its potential as a therapeutic agent for this condition.

This study found that platelet-rich plasma therapy may improve symptoms and quality of life in adults with moderate to severe atopic dermatitis, although standardized protocols for its preparation need further study.

In this study, patients with specific skin and scalp conditions, including eczematous lesions, showed significant improvement after two weeks of oral tofacitinib treatment, as evidenced by changes in the trunk lesions.

In this case report, a patient with severe atopic dermatitis experienced significant improvement with dupilumab after other treatments, including immunosuppressive agents, failed to control the disease.

In this study, human umbilical cord mesenchymal stem cells and their conditioned medium significantly improved symptoms in mouse models of atopic dermatitis, potentially through exosome-dependent pathways, suggesting a cell-free therapeutic strategy.

This study found that human placenta hydrolysate effectively inhibited atopic dermatitis development in stimulated human cells and a mouse model, suggesting its potential as a therapeutic agent for related skin diseases.

This study explored the associations between the skin microbiome and metabolome in groups LS, NL, and HC, suggesting potential new pathways for understanding scalp involvement in AD patients, which could improve management strategies.

This study reported that among five children and adolescents who developed new-onset atopic dermatitis after allogeneic hematopoietic stem cell transplantation, topical therapy and skin care improved their skin condition and atopic dermatitis severity scores, potentially reducing the need for excessive immunosuppressive therapy.

In this study, baricitinib treatment for severe alopecia areata showed similar safety and led to hair regrowth improvements independent of atopic background, with 40.8% of patients with atopy achieving a significant response compared to 30.2% without atopy when using a 4 mg dose.

This review analyzes the interplay between atopic dermatitis and alopecia areata, suggesting that epidermal barrier dysfunction and genetic predispositions exacerbate both conditions through immune responses.

This study presents a reported case where dupilumab treatment for atopic dermatitis led to improvement in alopecia universalis.

This study found that certain genetic variations in the OPN gene may be linked to atopic dermatitis and a higher prevalence of asthma in Caucasians.

This study observed that atopic dermatitis severity was associated with higher eosinophil counts and FLG variants, suggesting distinct endotypes that may require tailored treatment approaches.

This study found that a hypomorphic mutation in the Hr gene contributes to the development of diet-induced pruritic atopic skin in mice, particularly when combined with dietary deficiencies of polyunsaturated fatty acids and starch.

This article discusses the role of filaggrin gene mutations in understanding atopic dermatitis and their link to allergic sensitization but does not report new clinical results.

In this study conducted in female mice, maternal Faecalibacterium pathobionts combined with a low-fiber diet increased systemic inflammation and skin problems in offspring, suggesting a link to atopic dermatitis and the influence of dietary trends on chronic conditions.

This study reported that in a case series of three adolescents with alopecia areata and atopic dermatitis, treatment with 15 mg/day of upadacitinib led to rapid improvement in skin symptoms and significant hair regrowth over 12 months, with no severe adverse events observed.

In this case report, the authors described a 46-year-old woman with severe atopic dermatitis and alopecia areata, who experienced significant improvements in both conditions after treatment with the interleukin-13 blocker tralokinumab, suggesting a potential therapeutic role for targeting type 2 cytokine IL-13 in such cases.

This study found that alopecia areata patients in Central Europe with comorbid chronic inflammatory disorders, especially atopic dermatitis, bronchial asthma, or Hashimoto's thyroiditis, had an increased likelihood of experiencing early-onset, severe, or prolonged disease compared to those without such comorbidities.

This study suggests that keratinocytes derived from hair follicles of patients with atopic dermatitis provide a useful model for investigating AD-related inflammation, as they showed greater expression changes of AD markers when stimulated with type 2 cytokines compared to those from healthy donors.

This study reported that Taiwanese pre-teens and teenagers with atopic diseases, such as food allergies and asthma, had a significantly increased risk of developing alopecia areata, with the risk being 9.66 times higher compared to their peers without atopic conditions.

This review discusses the role of Janus-kinase inhibitors in treating severe atopic dermatitis and alopecia areata, presenting case studies that show their efficacy and calling for further research on long-term effectiveness and safety.

Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.

This study found that fermented red ginseng marc alleviated skin lesions, reduced inflammation, and demonstrated antioxidant effects in an AD-like mouse model, suggesting potential therapeutic applications for atopic dermatitis.

This study concluded that there was no consistent association between endogenous sex hormone levels and atopic dermatitis in the populations studied.

In this study, JAK inhibitors for treating alopecia areata and atopic dermatitis were generally well tolerated in a real-world setting, with most adverse events being mild or moderate and rare serious cases resembling the general population incidence.

A JAK1 variant causes hair loss, skin issues, and thyroid disease, but treatment with a specific inhibitor can help.

In this study, researchers developed a dissolvable microneedle patch combining HA-TEMPO and Portulaca oleracea L.-derived nanoparticles, which effectively reduced oxidative stress and inflammation in an atopic dermatitis model while restoring immune balance, suggesting a promising treatment strategy.